Current therapies for glioblastoma.
Yung
W K Alfred
WK
Department of Neuro-Oncology, University of Texas M. D. Anderson Cancer Center, TX, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002986:Clinical Trials as Topic; D016371:Cranial Irradiation; D003399:Craniotomy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015195:Drug Design; D015316:Genetic Therapy; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D010342:Patient Acceptance of Health Care; D011788:Quality of Life; D016372:RNA, Antisense / Q000627:therapeutic use; D012107:Research Design; D015996:Survival Rate; D000077204:Temozolomide; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D016372:RNA, Antisense; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D003606:Dacarbazine; D000077204:Temozolomide